



## SparingVision Announces €44.5 Million Equity Financing

Torreya served as exclusive placement agent to SparingVision

Paris, France, October 21, 2020

SparingVision ("the Company"), a genomic medicine company focused on ocular diseases, announced a €44.5 million equity financing round. The round was led by 4BIO Capital and UPMC Enterprises, and included Jeito Capital and Ysios Capital. In addition, current investors Bpifrance and Foundation Fighting Blindness participated in the round.

The proceeds from the financing will be primarily used to advance the development of the Company's breakthrough treatment SPVNo6 for the mutation-agnostic treatment of retinitis pigmentosa ("RP"). Most notably the funding will support SparingVision's GMP activities, the IND/CTA regulatory activities and the conduct of a first-in-man study, scheduled to start in 2021. The Company also intends to further expand its management team and commence operations in the US.

SPVNO6 is a proprietary, mutation-agnostic, AAV gene therapy consisting of one neurotrophic factor and one oxidative stress reducing enzyme which, acting synergistically, aim to slow or stop the degeneration of photoreceptors. Loss of photoreceptors leads to blindness in RP, one of the most common inherited retinal diseases that affects two million patients worldwide. There is currently no treatment approved for RP patients that is independent of their genetic background.

Torreya served as exclusive placement agent for the offering, reinforcing our long-standing expertise advising companies in the area of ophthalmic and genetic medicines. This was also Torreya's tenth deal in the ophthalmic area and to date, Torreya has completed almost 30 assignments in 2020.

### ABOUT SPARINGVISION:

For more information about SparingVision, please see: [www.sparingvision.com](http://www.sparingvision.com)

### Deal Press Release

#### Torreya Contact

**STEPHANIE LÉOUZON**

Partner | London Office

[stephanie.leouzon@torreya.com](mailto:stephanie.leouzon@torreya.com) | +44 (0) 207.451.4551 | [torreya.com](http://torreya.com)

**SPARINGVISION**  
GENOMIC MEDICINES FOR OCULAR DISEASES

Equity Financing Round

**€44.5 million**

**October 2020**

Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.